News Image

Why the dividend investor may take a look at NYSE:PFE.

By Mill Chart

Last update: Sep 27, 2023

PFIZER INC (NYSE:PFE) has caught the attention of dividend investors as a stock worth considering. NYSE:PFE excels in profitability, solvency, and liquidity, all while providing a decent dividend. Let's delve into the details.

A Closer Look at Dividend for NYSE:PFE

ChartMill employs its own Dividend Rating system for all stocks. This score, on a scale of 0 to 10, is determined by evaluating different dividend factors, such as yield, historical performance, dividend growth, and sustainability. NYSE:PFE has been assigned a 8 for dividend:

  • PFE has a Yearly Dividend Yield of 4.99%, which is a nice return.
  • Compared to an average industry Dividend Yield of 3.87, PFE pays a better dividend. On top of this PFE pays more dividend than 97.62% of the companies listed in the same industry.
  • PFE's Dividend Yield is rather good when compared to the S&P500 average which is at 2.64.
  • PFE has been paying a dividend for at least 10 years, so it has a reliable track record.
  • PFE has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.

Understanding NYSE:PFE's Health

ChartMill assigns a proprietary Health Rating to each stock. The score is computed by evaluating various liquidity and solvency ratios and ranges from 0 to 10. NYSE:PFE was assigned a score of 5 for health:

  • Looking at the Altman-Z score, with a value of 2.65, PFE is in the better half of the industry, outperforming 73.33% of the companies in the same industry.
  • PFE has a better Debt to FCF ratio (6.13) than 84.76% of its industry peers.
  • PFE has a Current Ratio of 2.12. This indicates that PFE is financially healthy and has no problem in meeting its short term obligations.

Exploring NYSE:PFE's Profitability

ChartMill utilizes a Profitability Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of profitability ratios and margins, both in absolute terms and in comparison to industry peers. NYSE:PFE has earned a 8 out of 10:

  • PFE's Return On Assets of 9.75% is amongst the best of the industry. PFE outperforms 90.95% of its industry peers.
  • PFE has a Return On Equity of 21.68%. This is amongst the best in the industry. PFE outperforms 91.90% of its industry peers.
  • PFE has a Return On Invested Capital of 11.96%. This is amongst the best in the industry. PFE outperforms 90.00% of its industry peers.
  • The 3 year average ROIC (16.16%) for PFE is well above the current ROIC(11.96%). The reason for the recent decline needs to be investigated.
  • Looking at the Profit Margin, with a value of 27.55%, PFE belongs to the top of the industry, outperforming 94.76% of the companies in the same industry.
  • With an excellent Operating Margin value of 31.21%, PFE belongs to the best of the industry, outperforming 95.71% of the companies in the same industry.
  • PFE's Operating Margin has improved in the last couple of years.
  • The Gross Margin of PFE (68.78%) is better than 73.81% of its industry peers.

Every day, new Best Dividend stocks can be found on ChartMill in our Best Dividend screener.

Our latest full fundamental report of PFE contains the most current fundamental analsysis.

Keep in mind

This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.



NYSE:PFE (11/30/2023, 12:24:10 PM)


+0.31 (+1.01%)

PFE News

News Image2 hours ago - Zacks Investment ResearchWhy Is Pfizer (PFE) Down 1.4% Since Last Earnings Report?

Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

News Image3 hours ago - Market News VideoPFE January 2024 Options Begin Trading
News Image4 hours ago - Zacks Investment ResearchThe Zacks Analyst Blog Highlights AbbVie, J&J, Eli Lilly, Pfizer

AbbVie, J&J, Eli Lilly, Pfizer are included in this Analyst Blog.

News Image4 hours ago - CNBCCovid vaccine rates in the U.S. are slumping — and it will be a challenge to boost them

The one thing that experts, along with vaccine makers, can agree on is that low vaccination rates put people at risk of getting severe Covid infections.

News Image18 hours ago - SBWireAnti-Inflammatory Drugs Market Boosting the Growth Worldwide 2030

Get Anti-inflammatory Drugs Market analysis, key vendors & competitive scenario of the market prepared using market research tools such as Porter’s five forces and SWOT analysis.

News Imagea day ago - InvestorPlace3 Synthetic Biology Stocks Likely to Mint New Millionaires

Synthetic biology stocks are strongly worth considering for several reasons, particularly these three stocks.

News Imagea day ago - Zacks Investment Research4 Large Drug Stocks to Watch as IBD Market Gains Traction

As demand for novel IBD treatments rises, investment in this dynamic sector could be rewarding. Some of the key players in the market are AbbVie (ABBV), J&J (JNJ), Lilly (LLY) and Pfizer (PFE).

News Imagea day ago - PRLogNew Partnership Between Generis And Risetime Provides Easy and Compliant Information Management for Cosmetics Industry

CHICAGO - Nov. 29, 2023 - PRLog -- Generis, developer of the CARA Platform for data, content, and business process management, and Risetime, provider of digital content management services for the beauty and life science industries today announced their partnership to offer our customers additional value-add services."We are absolutely thrilled about the incredible opportunities that this partnership brings to the table!" comments Patrick Windsor, Managing Director of Risetime. "By harnessing Risetime's exceptional expertise in FDA regulation and seamlessly integrating it with the cutting-edge CARA Platform, we're setting the stage for an extraordinary level of support to the Cosmetic and Beauty industries, ensuring their complete compliance with MoCRA regulations like never before!"The key focus of this partnership will be the configuration of the CARA Platform for the Cosmetic and Beauty industries and support of the current MoCRA FDA regulations. As a data and content management platform, CARA helps companies in regulated industries such as finance, energy, and manufacturing transform their complex business processes and remain compliant. The unified CARA Life Sciences Platform™ is the pre-configured, out-of-the-box layer with standardised apps for Regulatory, Quality, Safety, and Clinical processes, powered by a single structured data lake that gives users instant access to cross-functional data and enables powerful process optimisation for pharmaceutical companies. This partnership will allow Generis to further expand and fine-tune their offering for the Cosmetics industry."Our partnership with Risetime is a very exciting opportunity." commented James Kelleher, CEO of Generis. "Our CARA Platform provides rich functionality for companies across all regulated industries to remain compliant and keep up with the changing regulations, and with the expertise and guidance provided by the Risetime we can ensure that customers are thriving and improving the way their organisation works."About RisetimeRisetime is a Chicago-based service provider that offers exceptional services to clients across diverse industries with our skilled personnel and robust infrastructure.Our Digital Content Managers use their elevated understanding of healthcare and pharmaceutical industry requirements, to handle assets and metadata correctly in an FDA regulated industry.More at risetime.comAbout GenerisGeneris is a UK-headquartered developer of world-class data, content and business process management for regulated industries globally. 60% of the top 20 life sciences companies rely on Generis' flagship CARA™ Life Sciences Platform, including AbbVie, UCB, Biogen, Reckitt, Bristol Myers Squibb, Bayer, Pfizer, and Merck KGaA. Today Generis serves more than 750,000 users worldwide, across use cases ranging from RIM, Regulatory / R&D and Safety use cases to Clinical, Non-clinical, Quality GxP, CMC, Pharmacovigilance, Medical Information / Medical Affairs applications and more. More at generiscorp.com.

News Image2 days ago - Barron'sEight Beaten-Down Stocks Including Pfizer and Hasbro That Look Like Bargains

Some of the stocks dumped as funds do tax-loss selling can be attractive buys.

News Image2 days ago - Arvinas Inc.Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium
News Image2 days ago - Yahoo FinanceAWS expands cloud, AI relationship with big pharma players Pfizer, Amgen

Pfizer and Amazon Web Services are just another example of how artificial intelligence is working in the background in healthcare.

News Image2 days ago - Yahoo FinancePfizer disappointed in RSV shot's market share, CFO says

Pfizer Inc is disappointed in its performance versus rival GSK in the RSV vaccine market and is working to pick up market share in 2024, Chief Financial Officer David Denton said on Tuesday. Reuters reported in October that Pfizer's shot was lagging behind the GSK vaccine, which accounted for close to two-thirds of RSV shots given in the U.S. since early September. "If you look at our market share, I don't think we performed as well as we thought we could, or we think we will going forward," Denton told investors at a conference hosted by Evercore ISI analysts.

PFE Links
Follow us for more